After years of traditional coronary disease treatment involving the permanent fixation of a metal implant in the body, patients can now heave a sigh of relief as self absorbing stents are all set to revolutionize the cardiac medical domain. The drug eluting bioabsorbable vascular scaffold ABSORB, developed by the Vascular wing of pharmaceutical giant Abbott Laboratories (ABT) is the first of its kind that dissolves over time while facilitating blood flow in the diseased vessels.
ABSORB, proud winner of the 2011 Wall Street Journal Technology Innovation Awards in the Medical Devices category, was first launched for commercial use in Europe in January 2011 and more recently in September made available widely across Europe, parts of Asia pacific and Latin America.
India, became the latest to join the bandwagon of countries to implement the bioabsorbable stent treatment, and a Chennai-based Apollo hospital diabetic patient, 51 years of age, with two blockages became the first in the state of Tamil Nadu to successfully undergo the surgery.
"Bioabsorbable stents, such as Absorb, will broaden treatment and diagnostic options, reduce the need for long-term anti-platelet therapy and reduce the risk of in-stent restenosis and thrombosis," said Dr Sengottuvelu, a leading Interventional Cardiologist at Apollo and the doctor who performed the surgery.
However, unavailability of stents of all sizes and the need for a proper clearing of the blood vessel bed with a balloon before the scaffold replacement act as potential setbacks, said the doctor.
From bypass graft surgeries and balloon angioplasties in the 1970s, treatment for the deadly coronary disease has witnessed many a transformation to most recently enter the self-absorbing stent era. The treatment, apart from providing greater flexibility to the blood vessels is also expected to invalidate or reduce to a large extent, the need for a long-term dual anti platelet or blood-thinning therapy post treatment.
Post the complete absorption of the stent, blood vessels are expected to resume the normal contraction and relaxation function thus making it possible for a bypass graft to be situated in the very location, should it be deemed necessary in future.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org